Collegium Pharmaceutical (COLL) Projected to Post Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) will likely be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Collegium Pharmaceutical to post earnings of $1.89 per share and revenue of $191.2480 million for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 6, 2025 at 8:00 AM ET.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. The company had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a return on equity of 97.28% and a net margin of 5.13%. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $35.76 on Wednesday. The stock’s 50 day moving average is $35.65 and its 200 day moving average is $32.58. The company has a debt-to-equity ratio of 3.27, a current ratio of 1.18 and a quick ratio of 1.10. The firm has a market cap of $1.13 billion, a P/E ratio of 34.38 and a beta of 0.61. Collegium Pharmaceutical has a one year low of $23.23 and a one year high of $39.95.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on COLL shares. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 23rd. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Tuesday, October 28th. HC Wainwright raised Collegium Pharmaceutical to a “strong-buy” rating and set a $44.00 price target on the stock in a research note on Monday, August 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 18th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.33.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 16,389 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $38.21, for a total transaction of $626,223.69. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at $3,959,052.73. This represents a 13.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gino Santini sold 5,405 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $37.19, for a total value of $201,011.95. Following the transaction, the director directly owned 95,042 shares in the company, valued at $3,534,611.98. The trade was a 5.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 55,792 shares of company stock valued at $2,084,207 over the last ninety days. Company insiders own 2.51% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the company. Engineers Gate Manager LP raised its position in shares of Collegium Pharmaceutical by 165.7% during the second quarter. Engineers Gate Manager LP now owns 70,077 shares of the specialty pharmaceutical company’s stock worth $2,072,000 after purchasing an additional 43,705 shares during the period. PDT Partners LLC acquired a new position in shares of Collegium Pharmaceutical during the second quarter worth approximately $425,000. Qube Research & Technologies Ltd raised its position in Collegium Pharmaceutical by 77.1% in the 2nd quarter. Qube Research & Technologies Ltd now owns 94,880 shares of the specialty pharmaceutical company’s stock valued at $2,806,000 after buying an additional 41,315 shares during the last quarter. JPMorgan Chase & Co. raised its position in Collegium Pharmaceutical by 3.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock valued at $2,131,000 after buying an additional 2,592 shares during the last quarter. Finally, Jane Street Group LLC raised its position in Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after buying an additional 90,255 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.